Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Credit: University of California, San Diego

In the phase 2 RAPIDe-1 trial, oral deucrictibant significantly reduced the severity of 

attacks in 4 hours compared with the placebo.

“…these results support continued investigation of antagonism of the bradykinin B2 receptor with an orally available agent as a potentially effective approach, with a safety profile similar to placebo, for on-demand treatment,” wrote study investigators Marc A. Riedl, from the University of California San Diego; Emel Aygören-Pürsün, MD, from Goethe University Frankfurt; and colleagues.

Before the publication of this phase 2 data, Pharvaris announced that oral deucrictibant 20 mg met its primary endpoint in the placebo-controlled phase 3 trial, showing symptom relief in under 90 minutes.

The mean time to symptom relief with oral deucrictibant was within 1.28 hours, compared to > 12 hours with a placebo.

In the recently published phase 2 randomized, double-blind, placebo-controlled, crossover study, adults with HAE type 1 or 2 experienced clinically meaningful improvements in symptom burden and time to relief when treated with deucrictibant at doses of 20 mg or 30 mg.

 Among 62 patients included in the modified intention-to-treat analysis, deucrictibant demonstrated significant reductions in the composite visual analog scale (VAS-3) score at 4 hours compared with the placebo. Least squares mean differences were −15.02 (95% CI, −20.22 to −9.81; 

<.0001) for 20 mg and −16.28 (95% CI, −21.27 to −11.29; 

<.0001) for 30 mg. A 10 mg dose showed similar directional effects but was evaluated descriptively.

Clinical benefits extended to key secondary endpoints. Median time to onset of symptom relief, defined as a ≥ 30% reduction in VAS-3, was 2.7 hours for 20 mg and 2.5 hours for 30 mg, compared with 8.0 hours for placebo. Time to a ≥ 50% reduction in symptoms and to near-complete or complete resolution was also significantly shorter with deucrictibant. Within 24 hours, 71% of attacks treated with 20 mg and 74% with 30 mg achieved near-complete or complete resolution without rescue medication, compared with 16% of placebo-treated attacks.

Use of rescue therapy was lower with deucrictibant. Within 24 hours, 11% and 13% of attacks treated with 20 mg and 30 mg, respectively, required rescue medication versus 73% with placebo (odds ratios 0.05–0.06; 

<.0001). These findings suggest both rapid onset and durability of response.

The study reported no grade 3 or higher treatment-emergent adverse events. Most adverse events were mild to moderate and considered unrelated to the study drug. In part 2 of the trial, no single adverse event occurred in ≥ 2 patients within any treatment group. Oral administration avoids injection-site reactions commonly associated with subcutaneous bradykinin B2 receptor antagonists.

Pharmacokinetic data showed plasma concentrations exceeding the estimated threshold for 85% maximal response within 15 to 30 minutes of dosing, aligning with observed early clinical effects. Symptom improvement was detectable within the first hour across multiple outcome measures.

Current on-demand HAE therapies, including C1 esterase inhibitors, icatibant, and ecallantide, require intravenous or subcutaneous administration, which can delay treatment initiation. Although the recently approved plasma kallikrein inhibitor sebetralstat offers an oral option, deucrictibant represents the first oral bradykinin B2 receptor antagonist evaluated in a randomized controlled trial for acute HAE treatment, according to the investigators.

The team noted several limitations, including the exclusion of laryngeal attacks and those with vomiting, limiting generalizability to greater risk presentations. The study population was predominantly White, and the attack location was not randomized, which may influence response patterns.

Ongoing phase 3 studies are expected to further define the role of deucrictibant in both on-demand and prophylactic HAE treatment strategies. Investigators noted that the phase 3 trial will include a broader geographical and racial representation.

“Together with the results of the CHAPTER-1 trial (NCT05047185) for prophylaxis of angioedema attacks conducted in parallel, outcomes of RAPIDe-1 provide the first clinical evidence, to our knowledge, that antagonism of the bradykinin B2 receptor with deucrictibant could be effective and well tolerated and that deucrictibant might be the first oral therapy for both prevention and treatment of bradykinin-mediated angioedema attacks,” investigators concluded.

Maurer M, Stobiecki M, Valerieva A, et al. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial. 

Derman C. Pharvaris’ Deucrictibant Provides Rapid Relief for HAE in Phase 3 RAPIDe-3 Trial. HCPLive. Published December 8, 2025. Accessed on April 29, 2026. 

https://www.hcplive.com/view/pharvaris-deucrictibant-provides-rapid-relief-hae-phase-3-rapide-3-trial

Articles

Oral deucrictibant, a bradykinin B2 receptor antagonist, produced rapid, clinically meaningful improvement in acute hereditary angioedema (type 1/2), significantly lowering composite VAS symptom burden by 4 hours versus placebo. Median onset of relief occurred ~2.5–2.7 hours with 20–30 mg versus 8 hours with placebo, with markedly higher near-complete/complete resolution by 24 hours and substantially reduced rescue-medication use. Pharmacokinetics supported early efficacy, and tolerability was placebo-like without grade ≥3 events. Phase 3 data suggest symptom relief within ~90 minutes.

Phase 2 RAPIDe-1 trial shows an oral bradykinin B2 antagonist improves symptom relief and reduces rescue therapy use in hereditary angioedema attacks.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Oral Deucrictibant Reduces HAE Attack Severity in 4 Hours During Phase 2 RAPIDe-1

Mark G. Lebwohl, MD, the dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai,

Patient Preferences and Shared Decision-Making in Psoriasis Care

In this episode, ‘Patient Preferences and Shared Decision-Making in Psoriasis Care,’ the expert dermatologists explore the nuanced process of transition from topical to systemic therapy. Dr. Mark Lebwohl explains that while a 10% body surface area (BSA) often serves as a traditional threshold, systemic treatment is frequently necessary for patients with lower BSA if the psoriasis affects high-impact areas like the palms, soles, genitals, or hairline. He emphasizes that the National Psoriasis Foundation provides crucial support for clinicians to advocate for systemic options when a patient’s quality of life is significantly impaired, regardless of objective coverage scores.

Dr. Tina Bhutani-Jacques and Dr. Lebwohl discuss how they navigate the "shared decision-making" conversation by presenting patients with the full spectrum of modern options, including ultraviolet light, oral pills, and biologics. Dr. Lebwohl notes that specific patient needs—such as the requirement for rapid clearance before a wedding or a job interview—often push the choice toward faster-acting biologics. Conversely, comorbidities play a decisive role; for instance, IL-17 blockers are preferred for patients with multiple sclerosis, while they are avoided in those with Crohn's disease. The experts also touch on the "moderate" patient population, noting that while some oral therapies have broader labels for less severe disease, recent head-to-head trials show that many patients find the convenience of an injection every three months to be superior to a daily pill. The discussion concludes by reaffirming that because every patient defines convenience and success differently, a personalized, conversational approach is the only way to optimize long-term adherence and outcomes.

The next episode in this series, ‘Emerging Updates in Psoriasis from 2026 AAD Annual Meeting,’ features the panelists discussing late-breaking data regarding next-generation oral therapies and the dramatic synergy between weight-loss medications and psoriasis treatments. Dr. Bhutani-Jacques and Dr. Lebwohl explore how these combined approaches significantly improve skin clearance and systemic health.

Videos

Explore how cutting inflammation in psoriasis may lower heart risks, and why new oral TYK2 inhibitors could broaden treatment beyond injections.

Starting Treatment: Educating Patients and Initiating PERT for EPI

Once a diagnosis—or high clinical suspicion—is established, the panel turns to what comes next: patient education, treatment initiation, and supportive care coordination. Jennifer Geremia leads with the importance of educating patients that EPI is a long-term condition requiring long-term therapy. Without this foundational understanding, patients often stop therapy or take it inconsistently—since timing relative to meals is critical, any deviation compromises efficacy.

Sarah Enslin emphasizes setting realistic expectations from the start: patients should know what to anticipate in terms of timeframe for improvement and understand that dose adjustments are routine and do not indicate disease progression. She introduces the weight-based dosing framework and advises that providers build in a check-in at one to two weeks to assess and adjust. Capsules must always be taken with meals—not opened and sprinkled directly—though mixing with applesauce is acceptable as long as consumption is immediate.

The panel discusses ancillary support services with enthusiasm. Smoking and alcohol cessation are flagged as mandatory conversations, now embedded in their electronic health record workflows. Nutrition consults are described as transformative—a dietitian's ability to help patients maintain a pancreas-friendly diet within the constraints of their cultural preferences, financial resources, and lifestyle is something no provider can fully replicate. The shortage of dietitians in gastroenterology practice is explicitly called out as an unmet need.

Checking fat-soluble vitamin levels (A, D, E, K) at diagnosis and supplementing as needed is highlighted as an early, high-priority step. The panel also advocates for psychological support—particularly cognitive behavioral therapy—for patients who develop food fear or social anxiety. Palliative care is increasingly being invoked earlier in the care pathway, particularly for severely debilitated patients with chronic pancreatitis, to address pain and nutritional rehabilitation and break the cycle of repeated emergency department visits.

Optimizing PERT: Dosing, Adjustments, and Managing Non-Responders in EPI

," the panel provides practical guidance on fine-tuning PERT therapy—covering weight-based dosing, the role of PPIs, uric acid considerations, and strategies for patients who fail to respond to initial treatment.

Learn what happens after suspected EPI: patient education, enzyme therapy tips, nutrition and vitamin checks, plus smoking and alcohol support.

Video Series

Therapeutic Strategies in Wilson Disease

In this episode, 'Therapeutic Strategies in Wilson Disease,' the panelists explore the clinical decision-making process for managing copper toxicity. Dr. Rima Fawaz provides a foundational overview of current therapies, distinguishing between chelating agents—which bind to free, non-ceruloplasmin copper and promote renal excretion—and zinc therapy, which blocks intestinal copper absorption by inducing metallothionein. The experts also note recent findings suggesting that trientine may share some of zinc's absorption-blocking properties, adding a layer of mechanistic complexity to treatment selection.

A significant portion of the discussion focuses on the "low and slow" approach to starting chelation, particularly in patients with neurological symptoms. Dr. Peter Hedera explains the risk of paradoxical worsening, a phenomenon where the mobilization of copper can cause potentially irreversible neurological deterioration. Due to a lower perceived risk of this complication and a more favorable side-effect profile, trientine is often preferred over penicillamine for initial therapy. Conversely, zinc is identified as an ideal first-line option for asymptomatic patients or those diagnosed early through sibling screening, though its slow onset of action makes it unsuitable for acute de-coppering.

The panel emphasizes that Wilson disease requires lifelong maintenance, regardless of the initial therapy used. Whether staying on a reduced dose of a chelator or transitioning to zinc, the goal remains a stable, negative copper balance. Dr. Fawaz and Dr. Hedera conclude by highlighting the practical challenges of these regimens, such as the need to separate medications from food and each other, and the ongoing importance of monitoring 24-hour urine copper levels to guide long-term clinical success.

The next episode in this series, 'Evaluating Trientine Tetrahydrochloride in Wilson Disease from the CHELATE Trial,' features the panelists advancing their conversation on Wilson disease and focusing on the clinical advantages of newer chelation formulations. The experts discuss the transition from trientine dihydrochloride to the FDA-approved tetrahydrochloride salt, emphasizing improvements in storage, dosing frequency, and patient adherence.

Learn how chelators and zinc manage copper in Wilson disease, why trientine is favored, and when maintenance therapy becomes lifelong.

Impact of Early Diagnosis on Disease Progression and Quality of Life in Wilson Disease

This episode, titled 'Impact of Early Diagnosis on Disease Progression and Quality of Life in Wilson Disease,' features experts discussing the high stakes of clinical recognition and the evolving landscape of early detection. Dr. Rima Fawaz emphasizes that while no single test is perfectly diagnostic on its own, the emergence of newborn screening—such as the dried blood spot pilot in Washington state—is a monumental step toward identifying the condition before copper overload occurs. The panel notes that while genotype-phenotype correlations remain elusive, the ability to detect the ATP7B mutation at birth could change the trajectory of the disease for the 1 in 30,000 individuals affected.

The conversation shifts to the devastating consequences of untreated Wilson disease and the burden it places on patient quality of life. Dr. Peter Hedera outlines the severe neurological complications that can arise, including secondary dystonia, which may leave young patients mute, wheelchair-dependent, or requiring feeding tubes. He explains that unlike idiopathic Parkinson's disease, Wilson disease-related parkinsonism often fails to respond to standard symptomatic therapies, making early copper-clearing intervention the only effective path.

However, the panel also shares a message of hope. Both Dr. Fawaz and Dr. Hedera highlight that when caught early, even severe neurological symptoms like dysarthria and mobility issues can see near-complete reversal. This reinforces the "time is the enemy" mantra, as copper accumulates from the moment of conception. The episode concludes with a call for clinicians to be extremely aggressive with their index of suspicion, as the rewards of early treatment—returning a patient to a normal, functional life—are immense.

In the next episode, 'Therapeutic Strategies in Wilson Disease,' panelists will continue their discussion on Wilson disease and highlight the distinct mechanisms of copper chelators and zinc therapy. The experts compare first-line induction treatments for symptomatic patients with maintenance protocols and discuss the importance of lifelong management.

Newborn screening spots Wilson’s disease sooner, helping stop copper buildup and irreversible neurologic damage—improving outcomes and daily life.

Derm experts compare TYK2 pills with biologics for psoriasis—safety, speed, infections, and when combination therapy helps stubborn skin and joints.

Potential Therapeutic Opportunities of TYK2 Therapy Beyond Psoriasis and Identifying the Ideal Patient 

Clinicians weigh PEI questionnaires, symptom scores, and AGA updates to track exocrine pancreatic insufficiency and tailor patient-centered care.

Putting PROs to Work: The PEIQ and Symptom Scores in EPI Management

Podcasts

In this April episode, the discussion highlights how intentional choices and practice ownership can help physicians align professional with personal success.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

The Medical Sisterhood: Exposure is Power-Women in Medicine Creating Opportunity, With Elizabeth Kiracofe MD

Vinod E. Nambudiri, MD, MBA, MPH, is affiliated with Brigham and Women's Hospital and specializes in Dermatology and Internal Medicine.

This Q&A interview with Nambudiri covers the AAD Clinical Image Collection, launched in January 2025 to address diversity in dermatology education.



Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Q&A: How Dermatologists Can Utilize the AAD Clinical Image Collection, With Vinod Nambudiri, MD, MBA, MPH

Tatyana Kushner, MD, is an associate professor of medicine in the division of gastroenterology and hepatology at Weill Cornell Medicine.

Brelovitug achieved the FDA-specified primary endpoint for HDV RNA reduction and normalization of ALT in a phase 2b trial.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

AZURE-1: Brelovitug Meets Key Endpoints in Hepatitis D, With Tatyana Kushner, MD

Julie Silverstein, MD, is the medical director of the pituitary center and of the clinical trials unit and professor of medicine and neurological surgery at WashU Medicine.

Silverstein addresses a secondary analysis of the GRACE trial, highlighting relacorilant’s efficacy in reducing cortisol in patients taking GLP-1 RAs.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Relacorilant Reduces HbA1c in Cushing’s Despite GLP-1 Treatment, With Julie Silverstein, MD

Low-dose radiation therapy is gaining attention in the US for osteoarthritis and inflammatory pain, with clinicians citing anti-inflammatory effects.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Hospital Medicine

The HCPLive hospital medicine page is a comprehensive resource for clinical news and insights on the emergency medicine specialty. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for emergent care, and more.

Strategic Alliance Partnership

Low-Dose Radiation Therapy Gains Traction in US, With Hirsch Sudhir Matani, MD

Baba Inusa, MBBS, is a Consultant Paediatrician in the School of Life Course & Population Sciences at King's College London.

Inusa discusses how clinicians can close gaps in sickle cell disease care and global disparities. 

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Using SWAY’s Global Sickle Cell Data to Close Access, Treatment Gaps 

Shashank Joshi, MD, is a consultant endocrinologist at Liavati Hospital and Joshi Clinic in Mumbai.

Joshi explains the narrow window of optimal iodine levels, highlighting the risk posed by supplements and iodized salt in tipping the scales toward health risks.

Thyroid Disorders

Navigating Iodine Deficiencies and Excesses in Thyroid Health, With Shashank Joshi, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

The International Eczema Council set out to create a set of consensus-based definitions of remission, LDA, and vLDA in atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Latest News

Oral Deucrictibant Reduces HAE Attack Severity in 4 Hours During Phase 2 RAPIDe-1

Patient Preferences and Shared Decision-Making in Psoriasis Care

Starting Treatment: Educating Patients and Initiating PERT for EPI

Therapeutic Strategies in Wilson Disease

Impact of Early Diagnosis on Disease Progression and Quality of Life in Wilson Disease